Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic uses of l-4-chlorokynurenine

A technology of kynurenine and chlorination, which is applied to medical preparations containing active ingredients, metabolic diseases, pharmaceutical formulas, etc., and can solve problems such as limiting therapeutic efficacy

Inactive Publication Date: 2018-04-20
VISTAGEN THERAPEUTICS INC
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, directly acting (e.g., via channel blockade) NMDA-R antagonists produce numerous side effects, such as psychosis, which limit their therapeutic utility

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic uses of l-4-chlorokynurenine
  • Therapeutic uses of l-4-chlorokynurenine
  • Therapeutic uses of l-4-chlorokynurenine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1: Antihyperalgesic effect of L-4-chlorokynurenine on capsaicin-induced hyperalgesia.

[0054] On days 1 and 14 of the clinical study, two sequential intradermal injections of 250 μg capsaicin were injected into the volar side of the alternating forearm to produce burning pain, secondary hyperalgesia and flare. Capsaicin USP (United States Pharmacopoeia) was prepared according to standard procedures in the field and dissolved in 20% cyclodextrin at a concentration of 10 mg / mL.

[0055] The first capsaicin injection was administered in one forearm 1 hour after oral administration of L-4-chlorokynurenine or placebo and 2 hours after administration of L-4-chlorokynurenine or placebo A second capsaicin injection was given in the other forearm. Sensory nerve testing begins immediately with each capsaicin injection. Continuous pain was assessed using a 100-mm visual analog scale (VAS) before injection and at 0, 5, 10, 15, 30, 45, and 60 min after each capsaicin inje...

Embodiment 2

[0068] Example 2: Antidepressant activity of L-4-chlorokynurenine

[0069]Surprisingly, the inventors also discovered mood enhancing or antidepressant activity of L-4-chlorokynurenine. In the clinical study described in this application, 5 of 26 subjects (compared to zero subjects in the placebo group) reported affirmative feelings of well-being. This is consistent with reports that the glutamatergic system contributes to the pathophysiology of depression and that stress can induce changes in NMDA receptors. See, eg, Calabrese et al. 2012.

Embodiment 3

[0070] Example 3: Treatment of Major Depressive Disorder (MDD)

[0071] Twenty-five male and female patients aged 18 to 65 diagnosed with MDD were treated with L-4-chlorokynurenine (1080 mg / day or 1440 mg / day orally) for two weeks, similar in design to In similar studies [Ibrahim et al 2012, Zarate et al 2013, Zarate et al 2006, Zarate et al 2005]. Improvement in overall depressive symptoms was measured by either the Hamilton Depression Rating Scale (HDRS) [Hamilton 1959] and the Montgomery Asberg Depression Rating Scale (MADRS) total score or Significant reductions in both are shown [Montgomery et al 1979]. For a given patient, an additional measure of treatment efficacy may also be the proportion of subjects achieving remission (HDRS ≤ 7) and response (≥ 50% reduction in HDRS total score from baseline); changes from baseline in the following measures: Hamilton Anxiety The Hamilton Anxiety Rating Scale (HAM-A) [Hamilton 1959], the Columbia Suicide Severity Rating Scale (C-S...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses therapeutic uses of L-4-chlorokynurenine. Pharmaceutical compositions comprising L-4-chlorokynurenine and associated therapeutic methods are provided for the treatment of certain neurological and other conditions.

Description

[0001] Cross References to Related Applications [0002] This application is related to US Provisional Patent Application No. 62 / 179,924, filed May 22, 2015, and entitled "Therapeutic Uses of L-4-chlorokynurenine," the contents of which are hereby incorporated by reference in their entirety. [0003] Statement Regarding Federally Funded Research [0004] The data presented in this application are supported, at least in part, by grant number 2R44DA0 185 15-02 from the U.S. National Institutes of Health. The government has certain rights in this invention. technical field [0005] The present invention relates to compositions of L-4-chlorokynurenine (L-4-Cl-KYN) in unit dosage form and the use of these compositions for the treatment of neurological and other disorders. Background technique [0006] Glutamate is a major excitatory neurotransmitter in the mammalian central nervous system and is involved in the regulation of several different pathways. Excess endogenous glu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/135A61K31/198A61P25/24
CPCA61K45/06A61P25/18A61P25/02A61K31/198A61P3/10A61P25/24A61P27/16A61P25/00
Inventor H·拉尔夫·斯诺德格拉斯艾伦·E·卡多杰克·S·希克林
Owner VISTAGEN THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products